Donzé, C.; Leenhardt, F.; Vinches, M.; Eberlé, M.-C.; Fersing, C.
Clinical Pharmacy Initiatives Contribute to the Excellent Efficacy of the Dabrafenib/Trametinib Combination for Iodine-Refractory Thyroid Carcinoma: A Case Report. Medicina 2024, 60, 1037.
https://doi.org/10.3390/medicina60071037
AMA Style
Donzé C, Leenhardt F, Vinches M, Eberlé M-C, Fersing C.
Clinical Pharmacy Initiatives Contribute to the Excellent Efficacy of the Dabrafenib/Trametinib Combination for Iodine-Refractory Thyroid Carcinoma: A Case Report. Medicina. 2024; 60(7):1037.
https://doi.org/10.3390/medicina60071037
Chicago/Turabian Style
Donzé, Charlotte, Fanny Leenhardt, Marie Vinches, Marie-Claude Eberlé, and Cyril Fersing.
2024. "Clinical Pharmacy Initiatives Contribute to the Excellent Efficacy of the Dabrafenib/Trametinib Combination for Iodine-Refractory Thyroid Carcinoma: A Case Report" Medicina 60, no. 7: 1037.
https://doi.org/10.3390/medicina60071037
APA Style
Donzé, C., Leenhardt, F., Vinches, M., Eberlé, M.-C., & Fersing, C.
(2024). Clinical Pharmacy Initiatives Contribute to the Excellent Efficacy of the Dabrafenib/Trametinib Combination for Iodine-Refractory Thyroid Carcinoma: A Case Report. Medicina, 60(7), 1037.
https://doi.org/10.3390/medicina60071037